| scholarly article | Q13442814 |
| P2093 | author name string | Dawson C | |
| Lietman T | |||
| Blower S | |||
| Porco T | |||
| P2860 | cites work | The intrinsic transmission dynamics of tuberculosis epidemics | Q46436856 |
| Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example | Q46576089 | ||
| Experimental inclusion conjunctivitis in man. II. Partial resistance to reinfection. | Q54704782 | ||
| Networks of sexual contacts | Q61054844 | ||
| Severe endemic trachoma in Tunisia | Q33598912 | ||
| Trachoma and blindness in the Nile Delta: current patterns and projections for the future in the rural Egyptian population | Q33647282 | ||
| Kinetics of Chlamydia trachomatis clearance in patients with azithromycin, as assessed by first void urine testing by PCR and transcription-mediated amplification | Q37880371 | ||
| Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings | Q37881738 | ||
| Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection | Q37881922 | ||
| Trachoma: the forgotten cause of blindness | Q37883646 | ||
| Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis | Q37885516 | ||
| The treatment of non-gonococcal urethritis with single dose oral azithromycin | Q37886524 | ||
| Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study | Q37886640 | ||
| Extent and kinetics of genetic change in the omp1 gene of Chlamydia trachomatis in two villages with endemic trachoma | Q37886831 | ||
| Molecular epidemiology of trachoma in a Gambian village | Q37888145 | ||
| Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. | Q37889593 | ||
| Randomised controlled trial of single-dose azithromycin in treatment of trachoma | Q37890462 | ||
| Fifteen-month follow-up study of women infected with Chlamydia trachomatis | Q37910915 | ||
| The World Health Organization's programme for the prevention of blindness | Q37926006 | ||
| Drugs, sex and HIV : a mathematical model for New York City | Q41158885 | ||
| The epidemiology of trachoma in southern Malawi. | Q43315796 | ||
| The epidemiology of trachoma in central Tanzania | Q43547420 | ||
| Control strategies for tuberculosis epidemics: new models for old problems | Q44574516 | ||
| Predicting and preventing the emergence of antiviral drug resistance in HSV-2. | Q46053560 | ||
| Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure | Q46175870 | ||
| Quantifying the intrinsic transmission dynamics of tuberculosis | Q46372801 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 572-576 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Global elimination of trachoma: how frequently should we administer mass chemotherapy? | |
| P478 | volume | 5 |
| Q35143100 | A critical review of the SAFE strategy for the prevention of blinding trachoma |
| Q33293477 | A rationale for continuing mass antibiotic distributions for trachoma |
| Q34449132 | Active trachoma two years after three rounds of azithromycin mass treatment in Cheha District Gurage Zone, Southern Ethiopia |
| Q28476520 | Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial |
| Q57188840 | Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review |
| Q37855263 | Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial |
| Q34855220 | Assessment of transmission in trachoma programs over time suggests no short-term loss of immunity |
| Q24796784 | Blinding trachoma: a disease of poverty |
| Q28361082 | Can we eliminate trachoma? |
| Q53276003 | Childhood Mortality After Mass Distribution of Azithromycin: A Secondary Analysis of The PRET Cluster-Randomized Trial in Niger. |
| Q37215938 | Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine |
| Q40527784 | Coinfection Dynamics of Two Diseases in a Single Host Population |
| Q35590537 | Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year |
| Q50137998 | Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial |
| Q34768657 | Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? |
| Q24801543 | Current problems of perinatal Chlamydia trachomatis infections |
| Q53419672 | Disappearance of trachoma from Western Nepal. |
| Q29037878 | Eliminating Trachoma in Areas with Limited Disease |
| Q36021861 | Enhanced antibiotic distribution strategies and the potential impact of facial cleanliness and environmental improvements for the sustained control of trachoma: a modelling study |
| Q37165258 | Epidemiology and control of trachoma: systematic review. |
| Q33424445 | Estimating household and community transmission of ocular Chlamydia trachomatis |
| Q36825728 | Estimating the Future Impact of a Multi-Pronged Intervention Strategy on Ocular Disease Sequelae Caused by Trachoma: A Modeling Study |
| Q41431741 | Hamiltonian Analysis of Subcritical Stochastic Epidemic Dynamics. |
| Q35221151 | How reliable are tests for trachoma?--a latent class approach |
| Q34234851 | How to make epidemiological training infectious |
| Q57182012 | Identifying a sufficient core group for trachoma transmission |
| Q33496749 | Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution |
| Q36275318 | Improving our forecasts for trachoma elimination: What else do we need to know? |
| Q37114162 | Infectious syphilis in high-income settings in the 21st century |
| Q34758133 | Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety |
| Q46194465 | Mass antibiotics for trachoma and the Allee effect |
| Q58783462 | Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II) |
| Q28544875 | Mass drug administration for trachoma: how long is not long enough? |
| Q39016688 | Mass drug administration: the importance of synchrony |
| Q37866138 | Mass treatment with single-dose azithromycin for trachoma. |
| Q55229858 | Models of Trachoma Transmission and Their Policy Implications: From Control to Elimination. |
| Q35043690 | Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania |
| Q49925233 | Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. |
| Q30670495 | Possible changes in the transmissibility of trachoma following MDA and transmission reduction: implications for the GET2020 goals |
| Q24794184 | Predicting the emergence of drug-resistant HSV-2: new predictions |
| Q37685533 | Probabilistic forecasts of trachoma transmission at the district level: A statistical model comparison |
| Q40044389 | Products of Compartmental Models in Epidemiology |
| Q90250445 | Progress to Eliminate Trachoma as a Public Health Problem in Amhara National Regional State, Ethiopia: Results of 152 Population-Based Surveys |
| Q37855030 | Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania |
| Q37865086 | Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study |
| Q33405255 | Reduction and return of infectious trachoma in severely affected communities in Ethiopia |
| Q50109856 | Resource allocation to prevent trachomatous low vision among older individuals in rural areas of less developed countries |
| Q34037913 | Review of the evidence base for the 'F' and 'E' components of the SAFE strategy for trachoma control. |
| Q37867431 | Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. |
| Q28547443 | Short-term Forecasting of the Prevalence of Trachoma: Expert Opinion, Statistical Regression, versus Transmission Models |
| Q36202123 | Short-term forecasting of the prevalence of clinical trachoma: utility of including delayed recovery and tests for infection |
| Q37868938 | Strategies for control of trachoma: observational study with quantitative PCR. |
| Q37507914 | Strategies to control trachoma |
| Q64076887 | Stromal Fibroblasts Drive Host Inflammatory Responses That Are Dependent on Chlamydia trachomatis Strain Type and Likely Influence Disease Outcomes |
| Q33468392 | The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control |
| Q37179222 | The distribution of the prevalence of ocular chlamydial infection in communities where trachoma is disappearing |
| Q28484940 | The easiest children to reach are most likely to be infected with ocular Chlamydia trachomatis in trachoma endemic areas of Niger |
| Q35917181 | The effect of antibiotic treatment on active trachoma and ocular Chlamydia trachomatis infection. |
| Q35571651 | The efficacy of oral azithromycin in clearing ocular chlamydia: mathematical modeling from a community-randomized trachoma trial |
| Q37407454 | The epidemiological dynamics of infectious trachoma may facilitate elimination |
| Q47103856 | The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa |
| Q33388677 | The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up |
| Q28478260 | The potential contribution of mass treatment to the control of Plasmodium falciparum malaria |
| Q60300335 | The utility of serology for elimination surveillance of trachoma |
| Q44050718 | Towards the global elimination of trachoma |
| Q56040927 | Trachoma |
| Q56482142 | Trachoma |
| Q37849704 | Trachoma and antibiotic use: the 'A' in SAFE. |
| Q36980676 | Trachoma and poverty: unnecessary blindness further disadvantages the poorest people in the poorest countries |
| Q35895991 | Trachoma decline and widespread use of antimicrobial drugs |
| Q37864857 | Trachoma is still a pediatric disease |
| Q43418607 | Trachoma research: it takes more than a village |
| Q42840992 | Trachoma, antibiotics and randomised controlled trials |
| Q51067327 | Trachoma. |
| Q36830384 | Trachoma: transmission, infection, and control |
| Q37853415 | Travel and implications for the elimination of trachoma in ethiopia |
| Q37849443 | Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania |
| Q43008665 | What more is there to learn about trachoma? |
| Q35230503 | What's new in azithromyin? |
Search more.